Prognosis of small hepatocellular nodules detected only hepatobiliary phase of Gd-EOB-DTPA enhanced MR imaging as hyperintensity in cirrhosis or chronic hepatitis

Atsushi Higaki1, Tsutomu Tamada1, Akira Yamamoto1, Hiroki Higashi1, Akiko Kanki1, Yasufumi Noda1, Tomohiro Sato1, and Katsuyoshi Ito1

1Radiology, Kawasaki Medical School, Kurashiki city, Okayama, Japan

Target audience: Radiologist, physician.

Purpose: The purpose of this study was to evaluate the prognosis of small hepatocellular nodules which showed hyper-intensity at hepatobiliary phase and could not be detected at vascular phase and other conventional (e.g., T1, T2 and diffusion-weighted) sequences of initial Gd-EOB-DTPA enhanced MR imaging in patients with cirrhosis or chronic hepatitis.

Methods: A total of 139 patients with cirrhosis or chronic hepatitis who underwent Gd-EOB-DTPA enhanced MR imaging several times between January 2008 and January 2012 were investigated. Among these patients, 15 patients had 127 nodules which showed hyper-intensity at hepatobiliary phase but were not demonstrated in any other MR images including T1, T2 and diffusion-weighted MR images and dynamic vascular phase images. These 15 patients were included in this study (11 males and 4 females with a mean age of 65.2 years, range: 42-81 years). The underlying causes of chronic liver disease were B viral hepatitis (n=4), C viral hepatitis (n=5), Both B and C viral hepatitis (n=1), alcohol-induced hepatitis (n=3), and hepatitis of unknown etiology (n=1). All patients were found to have liver cirrhosis (Child A=14, Child B=1, Child C=0). These nodules were observed on the follow-up MR examinations until hypervascular nature was detected in the nodules on the arterial-phase images. The observation period, initial size of nodules, changes of nodule size during follow-up periods were also recorded.

Results: The median observation period of 127 nodules was 612 ± 390.4 days (range, 199 to 1366 days). The mean initial size of nodules was 10.3 ± 2.1 mm (range, 5.9 to 17.1 mm). There was no nodule showing hypervascular transformation during the follow-up periods. There was no nodule which showed increase in size more than 2 mm diameter during the follow-up periods. There was no significant difference between the nodule size of the initial (10.3 ± 2.1 mm) and latest (10.5 ± 2.2 mm) MRI examinations.

Discussion: In this study, there were no nodules which showed both hypervascularization and significant enlargement during follow-up periods. Short tumor-doubling times is one of the representative prognostic factors of HCC (1). Therefore, our results suggested that small hyper-intensity nodules at hepatobiliary phase without increase in size in this study might be clinically benign lesions. Some hyper-intensity nodules have been reported as hepatocellular adenoma (2) and HCC (3-5). However, these nodules had been already hypervascular on the initial MR examination. Accordingly, small hyper-intensity nodules in this study may not be the same as the nodules in these previous reports, because they could not be detected at vascular phase of Gd-EOB-DTPA enhanced MR imaging and other conventional sequences.

Conclusion: Our results indicate that small hepatocellular nodules which showed hyper-intensity at hepatobiliary phase but could not be detected at vascular phase and other conventional sequences of initial Gd-EOB-DTPA enhanced MR imaging in patients with cirrhosis or chronic hepatitis may be observable lesions with clinical benignity.

References:
5. Kitao A et al. Radiology 2010

Gd-EOB-DTPA-enhanced MR imaging

Precontrast  Arterial phase  Hepatobiliary phase